It has announced the final coupled cavity linac (CCL) module is ready for shipment to the Geneva testing facility.
The CCL unit used to generate a beam capable of treating superficial tumours when integrated with all the other components.
It means the LIGHT system remains on track to produce its first proton beam capable of treating cancer in the third-quarter of next year.
"The successful manufacture, performance testing and now delivery of the CCLs are a major milestone in the technological development of the LIGHT system,” said AVO chief executive Nicolas Serandour.
“For the first time, we will now have all of the key high-speed accelerating modules for LIGHT in place in our Geneva site and with a great deal of the manufacturing risk behind us, we can focus on the integration and commissioning of the individual components.
“This development brings the reality of the world's first linear proton accelerator in the treatment of cancer much closer."
At 1.25pm, the shares were up 5.6% at 16.62p.
---adds share price---